This is a working overview of certificate of analysis, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-12 and is reviewed periodically as new material appears.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
=== Secondhand cannabis smoke === A 2022 study found that smoking cannabis using a bong can greatly increase background levels of fine particulate matter, a carcinogen, in an enclosed space such as a living room. After 15 minutes, mean levels of particulate matter were more than twice the Environmental Protection Agency hazardous air quality threshold, and after 140 minutes, the concentrations were four times greater than those generated by smoking tobacco using a cigarette or hookah. This suggests secondhand cannabis smoke from bongs may present a health risk to non-smokers.
== Career == The research Horsley explored throughout the duration of her doctorate degree, which was supervised by Grace Pavlath, focused on the transcription factors involved in the development of skeletal muscle tissue. The lab that Horsley worked in discovered that smaller muscles in mice were associated with a lack of transcription factor NFATc2. She was able to determine that factor NFATc2 was a foundational component that allotted myoblast cells to fuse and develop muscle fibers. She also found that NFATc2 factor regulates the transcription of a cytokine, IL-4. Horsley later decided to shift away from muscle research to complete her postdoctoral training under the guidance of Elaine Fuchs at Rockefeller University. It was during this process that she investigated the factors that influence stem cell development in the skin, specifically the transcription of factor Blimp-1. After finding that eliminating the gene that encoded Blimp-1 led to oily skin in mice, Horsley discovered that Blimp-1 monitors the size of the sebaceous gland. In 2009, Horsley joined the faculty of Yale University and was promoted to an associate professor of dermatology in 2011, as well as the Maxine F. Singer '57 Assistant Professor of Molecular, Cellular and Developmental Biology.
Fission cross sections are a measurable property related to the probability that fission will occur in a nuclear reaction. Cross sections are a function of incident neutron energy, and those for 235U and 239Pu are a million times higher than 238U at lower neutron energy levels. Absorption of any neutron makes available to the nucleus binding energy of about 5.3 MeV. 238U needs a fast neutron to supply the additional 1 MeV needed to cross the critical energy barrier for fission. In the case of 235U however, that extra energy is provided when 235U adjusts from an odd to an even mass. In the words of Younes and Lovelace, "...the neutron absorption on a 235U target forms a 236U nucleus with excitation energy greater than the critical fission energy, whereas in the case of n + 238U, the resulting 239U nucleus has an excitation energy below the critical fission energy." About 6 MeV of the fission-input energy is supplied by the simple binding of an extra neutron to the heavy nucleus via the strong force; however, in many fissionable isotopes, this amount of energy is not enough for fission. Uranium-238, for example, has a near-zero fission cross section for neutrons of less than 1 MeV energy. If no additional energy is supplied by any other mechanism, the nucleus will not fission, but will merely absorb the neutron, as happens when 238U absorbs slow and even some fraction of fast neutrons, to become 239U.
Sources: en.wikipedia.org
Because the risks of warfarin – which is used to treat blood clots – in a relatively young and otherwise healthy population are low, while the risk of adverse physical and psychological outcomes for untreated transgender patients is high, prothrombotic mutations (such as factor V Leiden, antithrombin III, and protein C or S deficiency) are not absolute contraindications for hormonal therapy. A 2018 cohort study of 2842 transfeminine individuals in the United States treated with a mean follow-up of 4.0 years observed an increased risk of VTE, stroke, and heart attack relative to a cisgender reference population. The estrogens used included oral estradiol (1 to 10 mg/day) and other estrogen formulations. Other medications such as antiandrogens like spironolactone were also used. A 2025 Dutch retrospective cohort study reported lower or similar risks for arterial cardiovascular events, but an elevated risk of venous thromboembolism. In 2,714 transgender women receiving gender-affirming hormone therapy, with 23,907 person-years of follow-up during the observation period, the study found that after adjustment for socioeconomic status, transgender women had a lower risk of myocardial infarction, a similar risk of ischaemic cerebrovascular accident, and a higher risk of venous thromboembolism compared with general-population men. A 2019 systematic review and meta-analysis found an incidence rate of VTE of 2.3 per 1000 person-years with feminizing hormone therapy in transgender women.
=== Ethnic groups === According to the 2021 census, ethnically the Bromley town ward was 70.1% White, 54.0% were White British, White Irish 1.7%, Roma 0.4% and 14.0% Other White. Asians were 12.8%, Black were 7.4%, mixed 6.7% and other were 3.0%.
The polarisation can be calculated on the basis of higher-order Madelung constants and has to be included in the calculation of the lattice energy by using a generalised Born–Haber cycle. This reflects the fact that the covalent bond in the sulfur pair is inadequately accounted for by a strictly ionic treatment. Arsenopyrite has a related structure with heteroatomic As–S pairs rather than S-S pairs. Marcasite also possesses homoatomic anion pairs, but the arrangement of the metal and diatomic anions differs from that of pyrite. Despite its name, chalcopyrite (CuFeS2) does not contain dianion pairs, but single S2− sulfide anions.
==== Other expansion formats explored ==== After the expansion to 48 teams was approved on January 10, 2017, it was initially decided that the tournament would include 16 groups of 3 teams, with the top two teams of each group progressing to a round of 32. This format would have included 80 matches in total, with the maximum number of matches per team remaining at seven, although each team would have played one fewer group match than in the 2022 tournament. The tournament would still have been completed within 32 days. This format was chosen over three alternatives involving 40 to 48 teams, 76 to 88 matches, and a minimum of 1 to 4 matches per team. Critics of this format argued that the use of three-team groups with two teams progressing significantly increased the risk of collusion between teams. This prompted FIFA to suggest that penalty shootouts could be used to prevent draws in the group stage, although even then some risk of collusion would remain, as it was possible for the two teams playing the last group match to engineer a circle of death result that would allow both of them to qualify. The tournament format was finalized in 2023, with an announcement that there would be 12 groups of 4 teams.
Sources: en.wikipedia.org
In 1933, the French pharmaceutical company Laboratoires Rhône-Poulenc began to search for new antihistamines. In 1947, it synthesized promethazine, a phenothiazine derivative, which was found to have more pronounced sedative and antihistaminic effects than earlier drugs. A year later, the French surgeon Pierre Huguenard used promethazine together with pethidine as part of a cocktail to induce relaxation and indifference in surgical patients. Another surgeon, Henri Laborit, believed the compound stabilized the central nervous system by causing "artificial hibernation" and described this state as "sedation without narcosis". He suggested to Rhône-Poulenc that they develop a compound with better-stabilizing properties. In December 1950, the chemist Paul Charpentier produced a series of compounds that included RP4560 or chlorpromazine. Chlorpromazine was distributed for testing to physicians between April and August 1951. Laborit trialled the medicine at the Val-de-Grâce military hospital in Paris, using it as an anaesthetic booster in intravenous doses of 50 to 100 mg in surgery patients and confirming it as the best drug to date in calming and reducing shock, with patients reporting improved well being afterward. He also noted its hypothermic effect and suggested it may induce artificial hibernation. Laborit thought this would allow the body to better tolerate major surgery by reducing shock, a novel idea at the time. Following on, Laborit considered whether chlorpromazine may have a role in managing patients with severe burns, Raynaud's phenomenon, or psychiatric disorders.
5 July – The Fields Medal in mathematics is awarded to Hugo Duminil-Copin, June Huh, James Maynard and Maryna Viazovska. 2 December – Winners of the Earthshot Prize are announced, established in 2021 and awarded for developments useful for international climate change mitigation and sustainability goals.
== Research == Fischer and Jandera studied the effect of changing the concentration of methanol on CMC values for three commonly used surfactants. Two cationic, hexadecyltrimethylammonium bromide (CTAB), and N-(a-carbethoxypentadecyl) trimethylammonium bromide (Septonex), and one anionic surfactant, sodium dodecyl sulphate (SDS) were chosen for the experiment. Generally speaking, the CMC increased as the concentration of methanol increased. It was then concluded that the distribution of the surfactant between the bulk mobile phase and the micellar phase shifts toward the bulk as the methanol concentration increases. For CTAB, the rise in CMC is greatest from 0–10% methanol, and is nearly constant from 10–20%. Above 20% methanol, the micelles disaggregate and do not exist. For SDS, the CMC values remain unaffected below 10% methanol, but begin to increase as the methanol concentration is further increased. Disaggregation occurs above 30% methanol. Finally, for Septonex, only a slight increase in CMC is observed up to 20%, with disaggregation occurring above 25%. As has been asserted, the mobile phase in MLC consists of micelles in an aqueous solvent, usually with a small amount of organic modifier added to complete the mobile phase. A typical reverse phase alkyl-bonded stationary phase is used. The first discussion of the thermodynamics involved in the retention mechanism was published by Armstrong and Nome in 1981. In MLC, there are three partition coefficients which must be taken into account.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.